Get startedLog in
    Picture of Kalvista Pharmaceuticals logo

    KALV — Kalvista Pharmaceuticals News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapMomentum Trap
    All News

    Brief: EMA's CHMP Recommended Not Granting A Marketing Authorisation For Elevidys For Treatment Of Duchenne Muscular Dystrophy

    Picture of Kalvista Pharmaceuticals logoKalvista Pharmaceuticals
    25/07/2025 11:42
    Corrects to fix source

July 25 (Reuters) -

EMA'S CHMP: RECOMMENDED NOT GRANTING A MARKETING AUTHORISATION FOR ELEVIDYS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

EMA'S CHMP: EKTERLY RECEIVED POSITIVE OPINION FROM CHMP FOR THE TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Kalvista Pharmaceuticals

    See all news